NCT01397448 - Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study) | Biotech Hunter

Enrollment

472

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

June 30, 2013

Conditions

Gastric or Duodenal Ulcers Caused by Low-dose Aspirin

Interventions

DRUG

E3810

E3810 5 mg/day Group: Orally administered E3810 5 mg tablets and E3810 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.

DRUG

E3810

E3810 10 mg Group: Orally administered E3810 5 mg placebo tablets and 10 mg tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.

DRUG

Teprenone

Teprenone 150 mg/day Group: Orally administered E3810 5 mg placebo tablets and 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg capsules three times daily after each meal.

Trial Locations (49)

Unknown

Kasugai

Nagoya

Ichikawa

Chikushino-shi

Fukuoka

Kitakyushu

Koga

Gifu

Maebashi

Asahikawa

Sapporo

Tomakomai

Itami

Kobe

Hitachi

Fujisawa

Kawasaki

Sagamihara

Yokohama

Kochi

Hitoyoshi

Kumamoto

Kyoto

Ebino

Miyazaki

Chikuma

Matsumoto

Nagano

Suzaka

Nagasaki

Beppu

Ōita

Yufu

Daitō

Hirakata

Matsubara

Osaka

Takatsuki

Yao

Karatsu

Saga

Ureshino

Izumo

Hamamatsu

Shizuoka

Ohtawara

Mitaka

Setagaya City

Shinjuku

All Listed Sponsors

lead

Eisai Co., Ltd.

INDUSTRY